TRVN

0.00050.00%
MA

Mark A. Demitrack

Senior VP & Chief Medical Officer

Dr. Mark A. Demitrack, MD, has been Senior Vice President and Chief Medical Officer of Trevena, Inc. since May 21, 2018. Dr. Demitrack was Vice President of Clinical Strategy at Roivant Sciences, Inc. He has been Vice President of Clinical Research at Axovant Sciences Ltd. since June 6, 2017. Dr. Demitrack served as the Chief Medical Officer and Vice President of Neuronetics, Inc. Dr. Demitrack is a psychiatrist with several years of experience in the treatment and study of mood disorders and related conditions. He served as Assistant Vice President of Neuroscience at Wyeth Pharmaceuticals, where he directed post marketing clinical development in support of the Effexor XR brand. Prior to Wyeth, Dr. Demitrack served as Medical Director for the New Antidepressant Team at Lilly Research Laboratories. During his tenure at Lilly, he oversaw the registration development and NDA submission of the novel antidepressant, Duloxetine. Prior to his industry experience, he served as Assistant Professor of the University of Michigan Medical Center Department of Psychiatry where he pursued research activities in the neuroendocrine correlates of chronic fatigue syndrome and fibromyalgia and served as Director of the Michigan Eating Disorders Program. He has over several years of industry experience at large and small biopharmaceutical companies where he has led numerous CNS programs pre- and post-approval. Dr. Demitrack has published extensively on the neuroendocrinology of mood disorders. He completed a fellowship in clinical neuroendocrinology at the NIH. He completed residency training in psychiatry at the University of California San Francisco and received board-certification in adult psychiatry. Dr. Demitrack holds a B.A. from Columbia University and an M.D. from the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey.

Positions